The anti-malarial drug hydroxychloroquine has shot to fame, owing to its efficacy in shortening the time taken for recovery from COVID-19. Fewer side effects associated with these medicines are encouraging manufacturers in the hydroxychloroquine drugs market to boost their output capacities. Over-the-counter distribution and inexpensive nature of hydroxychloroquine are being preferred by caretakers in home quarantine environments. However, these drugs are under scrutiny for lab-controlled testing, since there is lack of evidence about human trails.
It has been found that hydroxychloroquine alone or in combination with azithromycin can reduce virus levels quicker. Such findings have prompted drug regulators in several countries, including India to approve the drug in restricted settings. Hydroxychloroquine is found to trigger a hyperactive response by the immune system, which helps to minimize the symptoms. These factors are likely to drive the hydroxychloroquine drugs market during the forecast period.
Request a sample to get extensive insights into the Hydroxychloroquine Drugs Market
The hydroxychloroquine drugs market is predicted to clock a robust CAGR of 10% during the forecast period. Hydroxychloroquine (Plaquenil) is considered as a disease-modifying anti-rheumatic drug. The high prevalence of joint pain and long-term disability in individuals has catalyzed the demand for hydroxychloroquine drugs. Plaquenil is being highly publicized for effectively reducing pain and swelling of arthritis.
An alarmingly high number of childhood arthritis cases and other autoimmune diseases are acting as key drivers for the hydroxychloroquine drugs market. However, the drug may lead to severe hypoglycemia. Thus, diabetic patients are advised to regularly monitor their blood sugar levels. On the other hand, it has been found that hydroxychloroquine is not effective against malaria in areas where chloroquine resistance has been reported. Hence, pharma companies are advocating a better understanding of poor quality drugs on malaria control.
To understand how our report can bring difference to your business strategy, Ask for a brochure
Hydroxychloroquine drugs are the gold standard for the treatment of malaria. However, in many cases, healthcare professionals have encountered drug resistance in patients, which is likely to affect the growth of the hydroxychloroquine drugs market. Poorly administered medicines and substandard treatments are affecting the sales of hydroxychloroquine drugs. Hence, manufacturers in the hydroxychloroquine drugs market are taking ques from the WorldWide Antimalarial Resistance Network (WWARN), which is facilitating study groups that generate a pooled analysis of the efficacy and safety of hydroxychloroquine drugs.
Freely available training courses, tools and resources are being employed to provide regional researchers with the knowledge and skills to generate high-quality antimalarial clinical data. As such, the FDA (Food and Drug Administration) approval for hydroxychloroquine is being highly preferred for rheumatoid arthritis and systemic lupus erythematosis treatment.
The global hydroxychloroquine drugs market is expected to cross US$ 1.9 Bn by 2030, as manufacturers are increasing their output capacities that cater to the treatment of systemic lupus erythematosus. Research into the wide-ranging effects of hydroxychloroquine reveals that several benefits involving decrease in disease flares and decline in the number of antigen-presenting cells in the skin are bolstering market growth.
The decline in the damage from disease over time and the hydroxychloroquine’s ability to delay absorption of ultraviolet light (UV) are helping pharma companies boost their production capacities. However, patients with retinal dystrophy or macular degeneration are susceptible to toxicity due to hydroxychloroquine administration. Hence, companies in the hydroxychloroquine drugs market are encouraging patients to conduct annual examinations with qualified retina specialists to control toxicity levels.
Stuck in a neck-to-neck competition with other brands? Request a custom report on Hydroxychloroquine Drugs Market
Analysts’ Viewpoint
Companies in the hydroxychloroquine drugs market have increased their output capacities during the COVID-19 pandemic. However, the FDA has issued a caution against hydroxychloroquine outside of hospital settings due to the potential risk of heart rhythm problems. Juvenile idiopathic arthritis and high prevalence of lupus in individuals are boosting the growth of the hydroxychloroquine drugs market. However, issues of drug resistance are being encountered by several healthcare professionals. Hence, pharma companies are designing data visualization and mapping tools to track the spread of drug resistance. Such data is being handed over to government-led surveillance agencies to introduce high-quality drugs in the market.
Hydroxychloroquine Drugs Market – Segmentation
TMR’s study on the global hydroxychloroquine drugs market includes information divided into three segments: disease indication, distribution channel, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global hydroxychloroquine drugs market have been discussed in detail.
|
Disease Indication |
|
|
Distribution Channel |
|
|
Region |
|
Hydroxychloroquine drugs market to surpass valuation US$ 1.9 Bn by 2030
Hydroxychloroquine drugs market is projected to expand at a CAGR of 10% from 2020 to 2030
Hydroxychloroquine drugs market is driven by rise in prevalence of malaria and rheumatoid arthritis, and increase in geriatric population
North America accounted for a major share of the global hydroxychloroquine drugs market and the trend is anticipated to continue during the forecast period
Key players in the global market include Sanofi, Amneal Pharmaceuticals, Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Zydus Cadila
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Hydroxychloroquine Drugs Market
4. Market Overview
4.1. Introduction & Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Global Hydroxychloroquine Drugs Market Analysis and Forecast, 2018–2030
5. Market Outlook
5.1. COVID-19 Pandemics Impact on Industry
5.2. Regulatory Scenario by Region/globally
5.3. Disease Prevalence & Incidence Rate globally with key countries
6. Global Hydroxychloroquine Drugs Market Analysis and Forecast, by Disease Indication
6.1. Introduction & Definition
6.2. Global Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2018–2030
6.2.1. Malaria
6.2.2. Rheumatoid Arthritis
6.2.3. COVID-19
6.2.4. Systemic Lupus Erythematosus
6.2.5. Others
6.3. Global Hydroxychloroquine Drugs Market Attractiveness Analysis, by Disease Indication
7. Global Hydroxychloroquine Drugs Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Global Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
7.2.1. Hospital Pharmacies
7.2.2. Retail Pharmacies
7.2.3. Online Pharmacies
7.3. Global Hydroxychloroquine Drugs Market Attractiveness Analysis, by Distribution Channel
8. Global Hydroxychloroquine Drugs Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Global Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Global Hydroxychloroquine Drugs Market Attractiveness Analysis, by Region
9. North America Hydroxychloroquine Drugs Market Analysis and Forecast
9.1. Introduction
9.2. North America Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2018–2030
9.2.1. Malaria
9.2.2. Rheumatoid Arthritis
9.2.3. COVID-19
9.2.4. Systemic Lupus Erythematosus
9.2.5. Others
9.3. North America Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. North America Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Country, 2018–2030
9.4.1. U.S.
9.4.2. Canada
9.5. North America Hydroxychloroquine Drugs Market Attractiveness Analysis
9.5.1. By Disease Indication
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Hydroxychloroquine Drugs Market Analysis and Forecast
10.1. Introduction
10.2. Europe Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2018–2030
10.2.1. Malaria
10.2.2. Rheumatoid Arthritis
10.2.3. COVID-19
10.2.4. Systemic Lupus Erythematosus
10.2.5. Others
10.3. Europe Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Europe Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Europe Hydroxychloroquine Drugs Market Attractiveness Analysis
10.5.1. By Disease Indication
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Hydroxychloroquine Drugs Market Analysis and Forecast
11.1. Introduction
11.2. Asia Pacific Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2018–2030
11.2.1. Malaria
11.2.2. Rheumatoid Arthritis
11.2.3. COVID-19
11.2.4. Systemic Lupus Erythematosus
11.2.5. Others
11.3. Asia Pacific Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Asia Pacific Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Hydroxychloroquine Drugs Market Attractiveness Analysis
11.5.1. By Disease Indication
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Hydroxychloroquine Drugs Market Analysis and Forecast
12.1. Introduction
12.2. Latin America Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2018–2030
12.2.1. Malaria
12.2.2. Rheumatoid Arthritis
12.2.3. COVID-19
12.2.4. Systemic Lupus Erythematosus
12.2.5. Others
12.3. Latin America Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Latin America Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Hydroxychloroquine Drugs Market Attractiveness Analysis
12.5.1. By Disease Indication
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Hydroxychloroquine Drugs Market Analysis and Forecast
13.1. Introduction
13.2. Middle East & Africa Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2018–2030
13.2.1. Malaria
13.2.2. Rheumatoid Arthritis
13.2.3. COVID-19
13.2.4. Systemic Lupus Erythematosus
13.2.5. Others
13.3. Middle East & Africa Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.4. Middle East & Africa Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Middle East & Africa Hydroxychloroquine Drugs Market Attractiveness Analysis
13.5.1. By Disease Indication
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competitive Landscape
14.1. Market Position Analysis, by Company, 2019
14.2. Company Profiles
14.2.1. Sanofi
14.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.1.2. Growth Strategies
14.2.1.3. SWOT Analysis
14.2.2. Amneal Pharmaceuticals, Inc.
14.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.2.2. Growth Strategies
14.2.2.3. SWOT Analysis
14.2.3. Mylan N.V.
14.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.3.2. Growth Strategies
14.2.3.3. SWOT Analysis
14.2.4. Teva Pharmaceutical Industries Ltd.
14.2.4.1. Company Overview (HQ, Business Segments)
14.2.4.2. Growth Strategies
14.2.4.3. SWOT Analysis
14.2.5. Novartis AG
14.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.5.2. Growth Strategies
14.2.5.3. SWOT Analysis
14.2.6. Zydus Cadila
14.2.6.1. Company Overview (HQ, Business Segments)
14.2.6.2. Growth Strategies
14.2.6.3. SWOT Analysis
14.2.7. Dr. Reddy’s Laboratories Ltd.
14.2.7.1. Company Overview (HQ, Business Segments)
14.2.7.2. Growth Strategies
14.2.7.3. SWOT Analysis
14.2.8. Sun Pharmaceutical Industries Ltd.
14.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.8.2. Growth Strategies
14.2.8.3. SWOT Analysis
14.2.9. Lupin Limited
14.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.9.2. Growth Strategies
14.2.9.3. SWOT Analysis
14.2.10. Prasco Laboratories
14.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.10.2. Company Financials
14.2.10.3. Growth Strategies
14.2.10.4. SWOT Analysis
List of Tables
Table 01: Global Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2018–2030
Table 02: Global Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 03: Global Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Region, 2018–2030
Table 04: North America Hydroxychloroquine Drugs Market Revenue (US$ Mn) Forecast, by Country, 2018–2030
Table 05: North America Hydroxychloroquine Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2018–2030
Table 06: North America Hydroxychloroquine Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 07: Europe Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 08: Europe Hydroxychloroquine Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2018–2030
Table 09: Europe Hydroxychloroquine Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 10: Asia Pacific Hydroxychloroquine Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 11: Asia Pacific Hydroxychloroquine Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2018–2030
Table 12: Asia Pacific Hydroxychloroquine Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 13: Latin America Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 14: Latin America Hydroxychloroquine Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2018–2030
Table 15: Latin America Hydroxychloroquine Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 16: Middle East & Africa Remote Patient Monitoring Devices Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 17: Middle East & Africa Hydroxychloroquine Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2018–2030
Table 18: Middle East & Africa Hydroxychloroquine Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2018–2030
List of Figures
Figure 1: Global Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, 2018–2030
Figure 2: Global Hydroxychloroquine Drugs Market Value Share, by Disease Indication, 2019
Figure 3: Global Hydroxychloroquine Drugs Market Value Share, by Distribution Channel, 2019
Figure 4: Global Hydroxychloroquine Drugs Market Value Share Analysis, by Disease Indication, 2019 and 2030
Figure 5: Global Hydroxychloroquine Drugs Market Attractiveness Analysis, by Disease Indication, 2020–2030
Figure 6: Global Hydroxychloroquine Drugs Market Revenue (US$ Mn), by Malaria, 2018–2030
Figure 7: Global Hydroxychloroquine Drugs Market Revenue (US$ Mn), by Rheumatoid Arthritis, 2018–2030
Figure 8: Global Hydroxychloroquine Drugs Market Revenue (US$ Mn), by COVID-19, 2018–2030
Figure 9: Global Hydroxychloroquine Drugs Market Revenue (US$ Mn), by Systemic Lupus Erythematosus, 2018–2030
Figure 10: Global Hydroxychloroquine Drugs Market Revenue (US$ Mn), by Others, 2018–2030
Figure 11: Global Hydroxychloroquine Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 12: Global Hydroxychloroquine Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Figure 13: Global Hydroxychloroquine Drugs Market Revenue (US$ Mn), by Hospital Pharmacies, 2018–2030
Figure 14: Global Hydroxychloroquine Drugs Market Revenue (US$ Mn), by Retail Pharmacies, 2018–2030
Figure 15: Global Hydroxychloroquine Drugs Market Revenue (US$ Mn), by Online Pharmacies, 2018–2030
Figure 16: Global Hydroxychloroquine Drugs Market Value Share Analysis, by Region, 2019 and 2030
Figure 17: Global Hydroxychloroquine Drugs Market Attractiveness Analysis, by Region, 2020–2030
Figure 18: North America Hydroxychloroquine Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 19: North America Hydroxychloroquine Drugs Market Value Share (%), by Country, 2019 and 2030
Figure 20: North America Hydroxychloroquine Drugs Market Attractiveness, by Country, 2020–2030
Figure 21: North America Hydroxychloroquine Drugs Market Value Share (%), by Disease Indication, 2019 and 2030
Figure 22: North America Hydroxychloroquine Drugs Market Attractiveness, by Disease Indication, 2020–2030
Figure 23: North America Hydroxychloroquine Drugs Market Value Share (%), by Distribution Channel, 2019 and 2030
Figure 24: North America Hydroxychloroquine Drugs Market Attractiveness, by Distribution Channel, 2020–2030
Figure 25: Europe Hydroxychloroquine Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 26: Europe Hydroxychloroquine Drugs Market Value Share, by Country/Sub-region, 2019–2030
Figure 27: Europe Hydroxychloroquine Drugs Market Attractiveness, by Country/Sub-region, 2019–2030
Figure 28: Europe Hydroxychloroquine Drugs Market Value Share (%), by Disease Indication, 2019 and 2030
Figure 29: Europe Hydroxychloroquine Drugs Market Attractiveness, by Disease Indication, 2020–2030
Figure 30: Europe Hydroxychloroquine Drugs Market Value Share (%), by Distribution Channel, 2019 and 2030
Figure 31: Europe Hydroxychloroquine Drugs Market Attractiveness, by Distribution Channel, 2020–2030
Figure 32: Asia Pacific Hydroxychloroquine Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 33: Asia Pacific Hydroxychloroquine Drugs Market Value Share (%), by Country/Sub-region, 2019 and 2030
Figure 34: Asia Pacific Hydroxychloroquine Drugs Market Attractiveness, by Country/Sub-region, 2020–2030
Figure 35: Asia Pacific Hydroxychloroquine Drugs Market Value Share (%), by Disease Indication, 2019 and 2030
Figure 36: Asia Pacific Hydroxychloroquine Drugs Market Attractiveness, by Disease Indication, 2020–2030
Figure 37: Asia Pacific Hydroxychloroquine Drugs Market Value Share (%), by Distribution Channel, 2019 and 2030
Figure 38: Asia Pacific Hydroxychloroquine Drugs Market Attractiveness, by Distribution Channel, 2020–2030
Figure 39: Latin America Hydroxychloroquine Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 40: Latin America Hydroxychloroquine Drugs Market Value Share, by Country/Sub-region, 2019–2030
Figure 41: Latin America Hydroxychloroquine Drugs Market Attractiveness, by Country/Sub-region, 2019–2030
Figure 42: Latin America Hydroxychloroquine Drugs Market Value Share (%), by Disease Indication, 2019 and 2030
Figure 43: Latin America Hydroxychloroquine Drugs Market Attractiveness, by Disease Indication, 2020–2030
Figure 44: Latin America Hydroxychloroquine Drugs Market Value Share (%), by Distribution Channel, 2019 and 2030
Figure 45: Latin America Hydroxychloroquine Drugs Market Attractiveness, by Distribution Channel, 2020–2030
Figure 46: Middle East & Africa Hydroxychloroquine Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 47: Middle East & Africa Remote Patient Monitoring Devices Market Value Share, by Country/Sub-region, 2019–2030
Figure 48: Middle East & Africa Remote Patient Monitoring Devices Market Attractiveness, by Country/Sub-region, 2019–2030
Figure 49: Middle East & Africa Hydroxychloroquine Drugs Market Value Share (%), by Disease Indication, 2019 and 2030
Figure 50: Middle East & Africa Hydroxychloroquine Drugs Market Attractiveness, by Disease Indication, 2020–2030
Figure 51: Middle East & Africa Hydroxychloroquine Drugs Market Value Share (%), by Distribution Channel, 2019 and 2030
Figure 52: Middle East & Africa Hydroxychloroquine Drugs Market Attractiveness, by Distribution Channel, 2020–2030
Figure 53: Global Hydroxychloroquine Drugs Market Share Analysis, by Company, 2019
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Hydroxychloroquine Drugs Market
